GlaxoSmithKline plc (GSK) announced Friday that an FDA panel of experts has voted in favor of its investigational medicine for anthrax, Raxibacumab.
According to the company, the panel members voted 16 to 1 in support of the clinical benefit of Raxibacumab for the treatment of inhalational anthrax, with one abstention. In addition, the committee voted unanimously 18-0 in favor of the risk-benefit profile of Raxibacumab.
Raxibacumab was developed by Human Genome Sciences, and came into GlaxoSmithKline's fold when it acquired Human Genome Sciences in July of this year.
According to Human Genome Sciences, Raxibacumab works by targeting anthrax toxins after they are released by the bacteria into the blood and tissues. But the current antibiotics, although can kill the anthrax bacteria, they are not effective against the deadly toxins that the bacteria produce.
The final decision of FDA on Raxibacumab is set for December 15, 2012. The FDA normally considers the recommendations of the panel though it is not bound to do so.
GSK closed Friday's trading down 2.63% at $43.68 on a volume of 7.47 million shares.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.